title: Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?
abstract: Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.
authors.affiliation: IRCCS - Centro Neurolesi "Bonino-Pulejo", Messina, Italy. mariagaluppo@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Galuppo
authors.forename: E
authors.initials: E
authors.lastname: Mazzon
authors.forename: S
authors.initials: S
authors.lastname: Giacoppo
authors.forename: O
authors.initials: O
authors.lastname: Bereshchenko
authors.forename: S
authors.initials: S
authors.lastname: Bruscoli
authors.forename: C
authors.initials: C
authors.lastname: Riccardi
authors.forename: P
authors.initials: P
authors.lastname: Bramanti
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002467:Cell Nucleus / Q000187:drug effects* / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D003600:Cytosol / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000068556:Interferon beta-1a / Q000627:therapeutic use; D000068576:Interferon beta-1b / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000069442:Natalizumab / Q000627:therapeutic use*; D021381:Protein Transport / Q000187:drug effects; D060449:Wnt Signaling Pathway; D051176:beta Catenin / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: C495270:CTNNB1 protein, human; D007155:Immunologic Factors; D000069442:Natalizumab; D051176:beta Catenin; D000068576:Interferon beta-1b; D000068556:Interferon beta-1a